+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 169 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589939
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Drugs In Development, 2022, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 7, 3, 32, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 8 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageCandidiasis - Overview
Candidiasis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Candidiasis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Candidiasis - Companies Involved in Therapeutics DevelopmentCandidiasis - Drug ProfilesCandidiasis - Dormant ProjectsCandidiasis - Discontinued ProductsCandidiasis - Product Development Milestones
Featured News & Press Releases
  • Mar 03, 2022: Rezafungin awarded Promising Innovation Medicine (PIM) Designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Invasive Candidiasis
  • Feb 10, 2022: SCYNEXIS announces positive results from its pivotal phase 3 CANDLE study of Oral Ibrexafungerp for prevention of recurrent vaginal yeast infections, clearing the way for regulatory submission and potential approval of additional indication by end of 2022
  • Dec 20, 2021: BREXAFEMME (ibrexafungerp tablets) added to major national formulary, providing access for millions more commercially insured patients
  • Dec 15, 2021: Hansoh Pharmaceutical Group announces that clinical trial approval of ibrexafungerp tablets
  • Dec 15, 2021: European Medicines Agency grants orphan medicinal product designation for SCYNEXIS’ innovative antifungal ibrexafungerp for the indication of invasive candidiasis
  • Dec 14, 2021: Cidara Therapeutics and Mundipharma announce positive topline results from the global Phase 3 pivotal ReSTORE trial of Rezafungin for the treatment of candidemia and invasive candidiasis
  • Dec 06, 2021: SCYNEXIS announces agreement with FDA on innovative strategy for approval of oral Ibrexafungerp for treatment of invasive candidiasis
  • Dec 01, 2021: BREXAFEMME (Ibrexafungerp Tablets) receives 2021 popular science best of what’s new award in the health category
  • Nov 29, 2021: SCYNEXIS to host Ibrexafungerp hospital pipeline update Call and KOL webcast for investors on December 6
  • Nov 24, 2021: Scynexis reports positive data from Phase III oral VVC treatment trial
  • Nov 09, 2021: SCYNEXIS announces successful completion of phase 1 trial evaluating intravenous (IV) formulation of ibrexafungerp
  • Nov 08, 2021: FDA grants Profounda Orphan Drug Designation approval for treatment of treatment of invasive candidiasis with miltefosine
  • Nov 04, 2021: Hengrui Medicine's Class 1 new drug SHR8008 for the treatment of fungal vaginitis will be submitted for marketing application
  • Nov 03, 2021: Mycovia Pharmaceuticals announces completion of partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 clinical study evaluating oteseconazole for treatment of acute vulvovaginal candidiasis (VVC) in China
  • Nov 02, 2021: Hyloris announces start of phase 2 study of Miconazole-Domiphen Bromide Vaginal Cream in vulvovaginal candidiasis
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Candidiasis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Candidiasis - Pipeline by AbGenics Life Sciences Pvt Ltd, 2022
  • Candidiasis - Pipeline by Autoimmune Technologies LLC, 2022
  • Candidiasis - Pipeline by Bakker Medical Srl, 2022
  • Candidiasis - Pipeline by Beta Pharma Inc, 2022
  • Candidiasis - Pipeline by Biokawthar Technologies SAS, 2022
  • Candidiasis - Pipeline by Biomendics LLC, 2022
  • Candidiasis - Pipeline by Biosergen AS, 2022
  • Candidiasis - Pipeline by Cidara Therapeutics Inc, 2022
  • Candidiasis - Pipeline by CSA Biotechnologies LLC, 2022
  • Candidiasis - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
  • Candidiasis - Pipeline by Destiny Pharma Plc, 2022
  • Candidiasis - Pipeline by Fox Chase Chemical Diversity Center Inc, 2022
  • Candidiasis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022
  • Candidiasis - Pipeline by General Biologicals Corp, 2022
  • Candidiasis - Pipeline by Grupo Ferrer Internacional SA, 2022
  • Candidiasis - Pipeline by Hennepin Life Sciences LLC, 2022
  • Candidiasis - Pipeline by Knight Therapeutics Inc, 2022
  • Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, 2022
  • Candidiasis - Pipeline by MicroRid Technologies Inc, 2022
  • Candidiasis - Pipeline by Mycovia Pharmaceuticals Inc, 2022
  • Candidiasis - Pipeline by Nanomerics Ltd, 2022
  • Candidiasis - Pipeline by Next Science Ltd, 2022
  • Candidiasis - Pipeline by Nosopharm SAS, 2022
  • Candidiasis - Pipeline by Novabiotics Ltd, 2022
  • Candidiasis - Pipeline by Novartis AG, 2022
  • Candidiasis - Pipeline by Oryn Therapeutics, 2022
  • Candidiasis - Pipeline by Osel Inc, 2022
  • Candidiasis - Pipeline by Pacgen Life Science Corp, 2022
  • Candidiasis - Pipeline by Pfizer Inc, 2022
  • Candidiasis - Pipeline by Profem GmbH, 2022
  • Candidiasis - Pipeline by Pulmocide Ltd, 2022
  • Candidiasis - Pipeline by Pulmonomy Inc, 2022
  • Candidiasis - Pipeline by Purna Female Healthcare, 2022
  • Candidiasis - Pipeline by REYON Pharmaceutical Co Ltd, 2022
  • Candidiasis - Pipeline by Riptide Bioscience Inc, 2022
  • Candidiasis - Pipeline by Sano Chemicals Inc, 2022
  • Candidiasis - Pipeline by Satellos Bioscience Inc, 2022
  • Candidiasis - Pipeline by Scynexis Inc, 2022
  • Candidiasis - Pipeline by Shaanxi Synthetic Pharmaceutical Co Ltd, 2022
  • Candidiasis - Pipeline by Stadius Biopharma LLC, 2022
  • Candidiasis - Pipeline by TGV Therapeutics, 2022
  • Candidiasis - Pipeline by Toltec Pharmaceuticals LLC, 2022
  • Candidiasis - Pipeline by Visterra Inc, 2022
  • Candidiasis - Pipeline by Wellstat Vaccines LLC, 2022
  • Candidiasis - Dormant Projects, 2022
  • Candidiasis - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Candidiasis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbGenics Life Sciences Pvt Ltd
  • Autoimmune Technologies LLC
  • Bakker Medical Srl
  • Beta Pharma Inc
  • Biokawthar Technologies SAS
  • Biomendics LLC
  • Biosergen AS
  • Cidara Therapeutics Inc
  • CSA Biotechnologies LLC
  • CSPC Pharmaceutical Group Ltd
  • Destiny Pharma Plc
  • Fox Chase Chemical Diversity Center Inc
  • FUJIFILM Toyama Chemical Co Ltd
  • General Biologicals Corp
  • Grupo Ferrer Internacional SA
  • Hennepin Life Sciences LLC
  • Knight Therapeutics Inc
  • Matinas BioPharma Holdings Inc
  • MicroRid Technologies Inc
  • Mycovia Pharmaceuticals Inc
  • Nanomerics Ltd
  • Next Science Ltd
  • Nosopharm SAS
  • Novabiotics Ltd
  • Novartis AG
  • Oryn Therapeutics
  • Osel Inc
  • Pacgen Life Science Corp
  • Pfizer Inc
  • Profem GmbH
  • Pulmocide Ltd
  • Pulmonomy Inc
  • Purna Female Healthcare
  • REYON Pharmaceutical Co Ltd
  • Riptide Bioscience Inc
  • Sano Chemicals Inc
  • Satellos Bioscience Inc
  • Scynexis Inc
  • Shaanxi Synthetic Pharmaceutical Co Ltd
  • Stadius Biopharma LLC
  • TGV Therapeutics
  • Toltec Pharmaceuticals LLC
  • Visterra Inc
  • Wellstat Vaccines LLC